Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2014 by Boehringer Ingelheim
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01647711
First received: July 16, 2012
Last updated: November 5, 2014
Last verified: November 2014

July 16, 2012
November 5, 2014
July 2012
July 2015   (final data collection date for primary outcome measure)
Determination of Maximally Tolerated Dose (MTD) of intermittent high-dose afatinib [ Time Frame: up to 18 months ] [ Designated as safety issue: No ]
Determination of Maximally Tolerated Dose (MTD) of intermittent high-dose afatinib [ Time Frame: up to 6 months ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01647711 on ClinicalTrials.gov Archive Site
  • Safety of afatinib as assessed by incidence and intensity of adverse events graded according to United States National Cancer Institute Common Terminology Criteria for Adverse Events (US NCI CTCAE) version 3.0 for both Parts A and B [ Time Frame: up to 24 months ] [ Designated as safety issue: No ]
  • Objective response rate for patients with EGFR T790M mutations according to RECIST v1.1 [ Time Frame: up to 24 months ] [ Designated as safety issue: No ]
  • Cmax of afatinib as determined on day 3 of course 1 for patients in Part A [ Time Frame: up to 24 months ] [ Designated as safety issue: No ]
  • Determination of dosage for expansion cohort in Part B [ Time Frame: up to 24 months ] [ Designated as safety issue: No ]
  • Incidence of hepatic injury [ Time Frame: up to 24 months ] [ Designated as safety issue: Yes ]
  • Safety of afatinib as assessed by incidence and intensity of adverse events graded according to United States National Cancer Insitute Common Terminology Criteria for Adverse Events (US NCI CTCAE) version 3.0 for both Parts A and B [ Time Frame: up to 6 months ] [ Designated as safety issue: No ]
  • Objective response rate for patients with EGFR T790M mutations according to RECIST v1.1 [ Time Frame: up to 6 months ] [ Designated as safety issue: No ]
  • Cmax of afatinib as determined on day 3 of course 1 for patients in Part A [ Time Frame: up to 6 months ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations
A Phase 1b Study of Intermittent Administration of High Doses of the Irreversible EGFR Inhibitor Afatinib as a Means of Achieving Plasma Levels Active Against Non-small Cell Lung Cancer With Known T790M Mutations

This trial is divided into Part A and Part B. The primary objective of Part A is to establish the Maximal Tolerated Dose of intermittent high dose afatinib. The primary objective of Part B is to assess the response rate of patients with non-small cell lung cancer with EGFR T790M mutations to a dose of intermittent afatinib established in Part A.

The secondary objective is to explore tumor response and tumor-derived biological markers of response to afatinib, as well as pharmacokinetic parameters of afatinib.

Not Provided
Interventional
Phase 1
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Carcinoma, Non-Small-Cell Lung
Drug: Dose escalation followed by treatment with MTD
Fixed 3+3 dose escalation; expansion of MTD cohort
Experimental: Afatinib
Establish the Maximal Tolerated Dose of a pulsatile, high-dose regimen of afatinib in patients with advanced solid tumors followed by treatment at that dose or a lower dose in patients with stage IV non-small cell lung cancer harboring EGFR T790M mutations who have progressed on therapy with a reversible tyrosine kinase inhibitor
Intervention: Drug: Dose escalation followed by treatment with MTD
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
45
July 2015
July 2015   (final data collection date for primary outcome measure)

Inclusion criteria:

Part A only:

  1. Patients with histologically confirmed advanced solid tumours that are metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective. Patients who refuse standard therapy are also eligible.

    Part B only:

  2. Pathologically confirmed diagnosis of Stage IV (M1a or b) non-small cell lung cancer
  3. Documented Epidermal Growth Factor Receptor (EGFR) T790M mutation
  4. Progression of disease on a reversible tyrosine kinase inhibitor within 30 days of starting study drug

    Parts A and B:

  5. Evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
  6. Age >/= to 18 years
  7. Eastern Cooperative Group (ECOG) performance status 0-1
  8. Adequate organ function
  9. Recovered from any previous therapy-related toxicity to </= to Grade 1 at study entry (except for stable sensory neuropathy </= Grade 2 and alopecia)
  10. Written informed consent
  11. Ability to take oral medication

Exclusion criteria:

Parts A and B:

  1. Chemotherapy, biological therapy, or investigational agents (except erlotinib or gefitinib) within 4 weeks prior to the start of study treatment
  2. Hormonal treatment within 2 weeks prior to the start of study treatment (continued use of anti-androgens and/or gonadorelin analogues for treatment of prostate cancer is permitted)
  3. Radiotherapy within two weeks prior to the start of study treatment (except palliative radiotherapy given for symptom control)
  4. Less than 3 days from prior treatment with gefitinib or erlotinib. Patients with adverse events related to gefitinib or erlotinib must recover to Grade 1 or less to be eligible.
  5. Major surgery within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the study
  6. Known hypersensitivity to afatinib or the excipients of any of the trial drugs
  7. History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association classification of 3, unstable angina or poorly controlled arrhythmia as determined by the investigator. Myocardial infarction within 6 months prior to starting study treatment
  8. Women of childbearing potential and men who are able to father a child, unwilling to be abstinent or use adequate contraception prior to study entry, for the duration of study participation and for at least 2 months after treatment has ended.
  9. Female patients of childbearing potential who are nursing; are pregnant; are not using an acceptable method of birth control, or do not plan to continue using this method throughout the study; and do not agree to submit to pregnancy testing required by this protocol
  10. Any history of or concomitant condition that, in the opinion of the investigator, would compromise the patient's ability to comply with the study or interfere with the evaluation of the efficacy and safety of the test drug
  11. Previous or concomitant malignancies at other sites, except effectively treated non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured
  12. Required treatment with any of the prohibited medications listed in this protocol that cannot be stopped for the duration of trial participation
  13. Known pre-existing Interstitial Lung Disease
  14. Any history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug (for example, Crohn's disease, ulcerative colitis, chronic diarrhea, malabsorption) in the opinion of the investigator
  15. Active hepatitis B infection (defined as the presence of Hepatitis B DNA), active hepatitis C infection (defined as the presence of Hepatitis C RNA) and/or known Human Immunodeficiency Virus carrier
  16. Prior participation in a blinded afatinib clinical study, unless permission to unblind was granted in consultation with the Clinical Monitor of the blinded study
  17. Meningeal carcinomatosis
  18. Patients with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued use of corticosteroids or have been on stable doses of corticosteroids for at least 4 weeks before starting study treatment. Any symptoms attributed to brain metastases must be stable for at least 4 weeks before starting study treatment
  19. QTc interval > 0.47 seconds as measured during screening procedures
Both
18 Years and older
No
Contact: Boehringer Ingelheim Call Center 1-800-243-0127 clintriage.rdg@boehringer-ingelheim.com
United States
 
NCT01647711
1200.121
Not Provided
Boehringer Ingelheim
Boehringer Ingelheim
Not Provided
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
Boehringer Ingelheim
November 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP